Dr. Reddy's Laboratories acquires Preferred A-1 shares of Edity Therapeutics
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
Ecolab’s continued leadership position on renowned sustainability indices demonstrates the company’s record of advancing sustainable growth
Innovent will supply sintilimab for the collaborated clinical trial
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
AHHL is primarily engaged in nursing care, in home primary care, physiotherapy at home, sample collection, post-operative/post-surgical care
The product is expected to be launched in December 2023
The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges
Furthering cell therapy ambition across oncology and autoimmune diseases
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
Subscribe To Our Newsletter & Stay Updated